Company news: Abbott; Amylin
Amylin is making the rounds among prospective buyers weeks after rejecting a $3.5 billion takeover bid by Bristol-Myers Squibb, Reuters reports. Amylin markets diabetes drugs Byetta and Bydureon. The company has hired legal and financial advisers in preparation for a sale, even as it works to fend off a suit by major investor Carl Icahn. The company declined comment on the matter.